Vor Biopharma Inc (VOR)
1.795
0.00 (0.00%)
USD |
NASDAQ |
May 20, 13:34
Vor Biopharma SG&A Expense (Quarterly): 8.004M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.004M |
| December 31, 2023 | 7.227M |
| September 30, 2023 | 7.71M |
| June 30, 2023 | 8.277M |
| March 31, 2023 | 8.507M |
| December 31, 2022 | 7.663M |
| September 30, 2022 | 7.226M |
| June 30, 2022 | 6.459M |
| March 31, 2022 | 7.52M |
| Date | Value |
|---|---|
| December 31, 2021 | 5.613M |
| September 30, 2021 | 5.677M |
| June 30, 2021 | 5.41M |
| March 31, 2021 | 4.789M |
| December 31, 2020 | 4.333M |
| September 30, 2020 | 3.643M |
| June 30, 2020 | 2.065M |
| March 31, 2020 | 1.707M |
| December 31, 2019 | 0.964M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.964M
Minimum
Dec 2019
8.507M
Maximum
Mar 2023
5.711M
Average
6.068M
Median
SG&A Expense (Quarterly) Benchmarks
| Masimo Corp | 159.90M |
| AnaptysBio Inc | 12.34M |
| Apellis Pharmaceuticals Inc | 129.50M |
| NovaBay Pharmaceuticals Inc | 3.346M |
| Palatin Technologies Inc | 2.033M |